The databook is designed to serve as a comprehensive guide to navigating this
sector. The databook focuses on market statistics denoted in the form of
revenue and y-o-y growth and CAGR across the globe and regions. A detailed
competitive and opportunity analyses related to radiopharmaceuticals market will
help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of
91.89% in
2024.
Horizon Databook has segmented the Global radiopharmaceuticals market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to
2030.
- Global Radiopharmaceuticals Product Outlook (Revenue, USD Million, 2018-2030)
- Diagnostics
- PET
- F-18
- SR-82/RB-82
- Illuccix (gallium Ga 68 gozetotide)
- Others
- PYLARIFY (piflufolastat F 18)
- SPECT
- TC-99m
- GA-67
- Others
- TL-201
- I-123
- Therapeutics
- Beta Emitters
- SM-153
- I-131
- Lu-177
- Others
- Y-90
- Re-186
- Alpha Emitters
- Brachytherapy
- Cesium-131
- Iridium-192
- Palladium-103
- Iodine-125
- Others
- Global Radiopharmaceuticals Application Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Lymphoma
- Urology
- Neurology
- Endocrine Tumor
- Pulmonary Scans
- Cardiology
- SPECT
- Therapeutic Applications
- PET
- Thyroid
- SPECT
- Therapeutic Applications
- Other
- Bone Metastasis
- SPECT
- Therapeutic Applications
- Global Radiopharmaceuticals End Use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Others
- Diagnostic Centers
Reasons to
subscribe to Global radiopharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of
Global radiopharmaceuticals market databook
-
Our clientele includes a mix of radiopharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed
overview of
global-level
data and insights on the Global radiopharmaceuticals market , including
forecasts for subscribers. This
global
databook contains high-level insights into
Global radiopharmaceuticals market from
2018 to
2030, including revenue
numbers, major trends, and company profiles.